DanCann Pharma was founded in 2018 and is a Danish pharmaceutical biotechnology company powered by cannabinoids. DanCann Pharma is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma makes and distributes prescription (Rx-pharmaceuticals) and over-the-counter (OTC) pharmaceuticals mainly focused on pain patients with alternative needs and management to handle their illness, covered by the Danish Pilot Programme for medical cannabis – with future targets for further and new patient groups and segments.

Quotes for DanCann Pharma A/S

Right Now

+/-
-0.095
%
-2,87%
Latest
3.21
High
3.42
Low
3.2
Volume
151 992
Turnover (DKK)
494 094
Value (MDKK)
66,5

Board

CEO

  • Jeppe Krog Rasmussen

Chairman Of The Board

  • Magnus Østergaard Dahlmann

Board

  • Carsten Trads
  • Jeppe Krog Rasmussen
  • Per Wester

Largest Owners

Name Capital % Votes % Date
Jeppe Krog Rasmussen 25,47 25,47 2020-11-12
JJV Invest AB 8,36 8,36 2020-11-12
Futur Pension 6,01 6,01 2020-11-12
Morten Martinsen 1,93 1,93 2020-11-12
Hansen & Nytoft Invest Aps 1,45 1,45 2020-11-12
Vavi Invest Aps 0,96 0,96 2020-11-12
JBJensen ApS 0,58 0,58 2020-11-12
Per Wester 0,54 0,54 2020-11-12
Heroed Aps 0,49 0,49 2020-11-12
Carsten Trads 0,11 0,11 2020-11-12
Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Upcoming reports

  • 2021-02-19 Bokslutskommuniké 2020

  • 2021-03-21 Årsstämma 2020

  • 2021-05-05 Delårsrapport 2021-Q1

  • 2021-08-04 Delårsrapport 2021-Q2

  • 2021-11-03 Delårsrapport 2021-Q3